Cyanobacterial natural products as sources for antiviral drug discovery against COVID-19

Jafari Porzani S., Konur O., Nowruzi B.

Journal of Biomolecular Structure and Dynamics, 2021 (Journal Indexed in SCI Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume:
  • Publication Date: 2021
  • Doi Number: 10.1080/07391102.2021.1899050
  • Title of Journal : Journal of Biomolecular Structure and Dynamics


© 2021 Informa UK Limited, trading as Taylor & Francis Group.The recent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), positive-sense RNA viruses, originated from Wuhan City in December 2019 and propagated widely globally. Hence, the disease caused by this virus has been declared as a global pandemic by the WHO. As of 18th February 2021, at least seven different vaccines across three platforms have been rolled out in countries and more than 200 additional vaccine candidates have been in development, of which more than 60 are at the stage of the clinical development. So far, Most of the approved vaccine manufacturers are Pfizer, AstraZeneca, and Serum Institute of India, which have been finalized by WHO. Synthetic drug-associated complications have evoked scientific attention for natural product-based drugs. There has been a surge in the antiviral compounds from natural resources along with some therapies. Cyanobacteria are the fruitful reservoir of many metabolites like sulfated polysaccharides and lectins that possess strong antiviral activities and immunity boosting effects. However, the research in this field has been relatively under-developed. The current research highlights important features of cyanobacterial antiviral biomaterials, benefits and drawbacks of cyanobacterial drugs, challenges, future perspectives as well as overview of drugs against COVID-19. In addition, we have described mutated variants and transmission rate of coronaviruses. The current research suggests that cyanobacterial species and their extracts have promising applications as potentially antiviral drug biomaterials against COVID-19. Communicated by Ramaswamy H. Sarma.